Global Nuclear Medicine/Radiopharmaceuticals Market Size Study & Forecast, by Type (Diagnostic (SPECT-Technetium, PET-F-18), Therapeutic (Beta Emitters-Y-90, Alpha Emitters, Brachytherapy)), by Application (Neurology, Thyroid, Oncology) and Regional Forec

Valued at approximately USD 6.76 billion in 2024, the Global Nuclear Medicine/Radiopharmaceuticals Market is poised to expand at a robust CAGR of 11.30% over the forecast period 2025-2035. Nuclear medicine, an advanced medical specialty, leverages radiopharmaceuticals to diagnose, monitor, and treat a spectrum of diseases with unparalleled precision. These specialized compounds, infused with radioactive isotopes, play an indispensable role in modern healthcare by enabling early disease detection and targeted therapies that minimize collateral damage to healthy tissue. The surge in chronic disease prevalence, coupled with the rising adoption of personalized medicine and targeted oncology treatments, has propelled demand for nuclear medicine solutions. Additionally, the rapid pace of technological innovation in imaging modalities and isotope production is further reinforcing the market’s growth trajectory.

The market’s momentum is being fueled by the increasing volume of diagnostic procedures such as PET and SPECT scans, which have become standard in oncology, cardiology, and neurology assessments. As cancer and neurological disorders continue to affect millions globally, nuclear medicine offers a high-sensitivity, non-invasive method to detect abnormalities at their earliest stages, dramatically improving patient outcomes. According to the World Nuclear Association, over 40 million nuclear medicine procedures are performed annually worldwide, with demand expanding at around 5% each year. Furthermore, the therapeutic radiopharmaceuticals segment is gaining remarkable traction due to its proven efficacy in targeted cancer therapy, including prostate and thyroid cancers, as well as its application in pain palliation for bone metastases. However, challenges such as the short half-life of radioisotopes, complex regulatory pathways, and high production costs remain as factors that could temper the market’s rapid expansion.

Regionally, North America currently commands the lion’s share of the market, underpinned by its advanced healthcare infrastructure, strong research and development capabilities, and widespread adoption of cutting-edge diagnostic technologies. The region benefits from favorable reimbursement frameworks, robust investments in isotope production facilities, and a high concentration of specialized nuclear medicine centers. Meanwhile, Asia Pacific is projected to witness the fastest growth during the forecast period, driven by a rising incidence of chronic diseases, expanding healthcare access, and government-backed initiatives to bolster domestic isotope production in countries like China, India, and Japan. Europe also represents a substantial market, benefiting from established nuclear medicine networks and cross-border collaborations in research and clinical trials, particularly in countries such as Germany, France, and the UK.

Major market player included in this report are:
• Bayer AG
• Cardinal Health, Inc.
• GE Healthcare
• Jubilant Pharmova Limited
• Lantheus Holdings, Inc.
• Siemens Healthineers AG
• Bracco Imaging S.p.A
• Advanced Accelerator Applications (a Novartis company)
• Curium Pharma
• Nordion Inc.
• Eczacıbaşı-Monrol Nuclear Products Co.
• Telix Pharmaceuticals Limited
• IBA Radiopharma Solutions
• NorthStar Medical Radioisotopes, LLC
• Isotopia Molecular Imaging Ltd.

Global Nuclear Medicine/Radiopharmaceuticals Market Report Scope:
• Historical Data – 2023, 2024
• Base Year for Estimation – 2024
• Forecast period – 2025-2035
• Report Coverage – Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope – North America; Europe; Asia Pacific; Latin America; Middle East & Africa



The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players.

The detailed segments and sub-segments of the market are explained below:

By Type:
• Diagnostic

o SPECT (Technetium)

o PET (F-18)
• Therapeutic

o Beta Emitters (Y-90)

o Alpha Emitters

o Brachytherapy

By Application:
• Neurology
• Thyroid
• Oncology

By Procedures

By End User

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico

Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. Show more